Skip to main content
    A

    Arcus Biosciences Inc (RCUS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $16.40
    -0.46 (-2.73%)

    Market Cap: $2.43B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Arcus Biosciences Inc (RCUS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Arcus Biosciences (RCUS) has a market cap of $2.43B and an enterprise value of $2.38B. It kept -453.00% of revenue as net income over the last 12 months. Its share count is up 19.62% from a year earlier.

    Total Valuation

    Enterprise value is 2.02% below the market cap, as cash exceeds debt.

    Market Cap$2.43B
    Enterprise Value$2.38B
    Latest price (Nov 17, 2026)$16.40

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.03% in the quarter ended Sep 30, 2026 and grew 18.06% a year over 2 years.

    Shares Outstanding127.40M
    Shares Change (YoY)+19.62%
    Shares Change (QoQ)+1.03%
    Share Count Growth (2Y CAGR)+18.06%

    Valuation Ratios

    Sales and book value multiples are 20.9x and 5.8x. Its year-end P/S ranged from 5.1x to 36.2x from 2018 to 2025.

    P/S Ratio20.9x
    Forward P/S33.5x
    P/B Ratio5.8x

    Valuation history and multiples

    Price Statistics

    The stock is down 18.29% over 52 weeks and trades 25.83% below its 50-day average.

    Beta (1Y)1.59
    52-Week Change-18.29%
    1-Month Change-25.93%
    3-Month Change-45.96%
    6-Month Change-27.91%
    5-Year Change-45.60%
    Total Return (1Y)-18.29%
    Total Return (3Y CAGR)+4.21%
    Total Return (5Y CAGR)-17.75%
    Return vs SPY (1Y)-30.33%
    Max Drawdown (1Y)-48.05%
    Max Drawdown (3Y)-65.96%
    Sharpe Ratio (1Y)-0.33
    Correlation with SPY (1Y)0.34
    50-Day Average$22.11
    200-Day Average$24.42
    52-Week Range$16.76 to $31.73
    RSI (14 Days)31.2
    Average Volume (20 Days)2.31M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.34x current liabilities, and total debt is 0.28x shareholder equity.

    Current Ratio3.34x
    Quick Ratio3.34x
    Debt / Equity0.28x
    Interest Coverage-40.18x

    Returns and Efficiency

    Return on invested capital is -75.91% over the last 12 months, against a 5-year average of -37.34%.

    Return on Equity (ROE)-126.54%
    Return on Assets (ROA)-55.38%
    Return on Invested Capital (ROIC)-75.91%
    Return on Capital Employed (ROCE)-71.41%
    ROE (5Y Average)-43.02%
    ROA (5Y Average)-20.03%
    ROIC (5Y Average)-37.34%
    Asset Turnover0.11x

    Scores

    RCUS has an Altman Z-Score of -1.39, in the distress zone below 1.81, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.39
    Altman Z ZoneDistress
    Piotroski F-Score0 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $100.00M over the last 12 months is down 58.33% from the 12 months before.

    Revenue$100.00M
    Revenue Growth (YoY)-58.33%
    Gross Profit$100.00M
    Operating Income-$475.00M
    Pretax Income-$453.00M
    Net Income-$453.00M
    EBITDA-$442.00M
    EBIT-$442.00M
    Reported EPS (TTM)-$3.63

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 43.77% of the $818.00M in total assets.

    Cash and Equivalents$151.00M
    Total Debt$102.00M
    Net Cash$49.00M
    Net Cash Per Share$0.38
    Working Capital$465.00M
    Shareholder Equity$358.00M
    Book Value Per Share$2.81
    Total Assets$818.00M
    Total Liabilities$460.00M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$465.00M
    FCF Per Share-$3.71
    Depreciation and Amortization$20.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -475.00%.

    Gross Margin100.00%
    Operating Margin-475.00%
    Pretax Margin-453.00%
    Net Margin-453.00%
    EBITDA Margin-442.00%
    EBIT Margin-442.00%

    Growth

    Revenue grew 30.16% a year over 3 years.

    Revenue Growth (3Y CAGR)+30.16%
    Revenue Growth (5Y CAGR)+25.93%
    Book Value Per Share Growth (2Y CAGR)-2.34%
    Tangible Book Per Share Growth (2Y CAGR)-2.34%

    Revenue and profit by year

    Dividends and Yields

    RCUS does not pay a dividend.

    Buyback Yield-14.93%
    Shareholder Yield-14.93%

    Peer Position

    Against 8 similar companies, RCUS has the 2nd highest P/S.

    P/S Ratio20.9x vs 8.1x median
    ROIC-75.91% vs -27.46% median
    Revenue Growth (Trailing 4 Quarters, YoY)-58.33% vs +25.30% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -56.83% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-56.83%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RCUS

    What is RCUS's market cap?

    Arcus Biosciences has a market cap of $2.43B. Its enterprise value, which adds debt and subtracts cash, is $2.38B.

    How many shares of RCUS are outstanding?

    Arcus Biosciences has 127.40M shares outstanding. The count is up 19.62% from a year earlier.

    Does RCUS pay a dividend?

    No. Arcus Biosciences does not pay a dividend.

    How much debt does RCUS have?

    Arcus Biosciences has $102.00M of total debt and $151.00M of cash and equivalents, a net cash position of $49.00M.